CCRN · Cross Country Healthcare Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $241.06M | - | $250.05M | $274.07M | $293.41M | - | $315.12M | $339.77M | $379.17M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $45.81M | - | $46.89M | $50.05M | $52.49M | - | $54.30M | $60.26M | $63.25M | - |
| Total Operating Expenses | $245.21M | - | $256.02M | $279.93M | $294.38M | - | $312.27M | $358.98M | $376.25M | - |
| D&A | $3.67M | - | $4.09M | $4.10M | $4.77M | - | $4.50M | $4.72M | $4.64M | - |
| Operating Income | ($4.16M) | - | ($5.97M) | ($5.86M) | ($977.0K) | - | $2.85M | ($19.21M) | $2.92M | - |
| Interest Expense | $567.0K | - | $556.0K | $549.0K | $462.0K | - | $550.0K | $568.0K | $462.0K | - |
| Income Tax | $532.0K | - | ($863.0K) | $930.0K | ($409.0K) | - | $834.0K | ($3.51M) | $997.0K | - |
| Net Income | ($4.27M) | - | ($4.77M) | ($6.66M) | ($490.0K) | - | $2.56M | ($16.05M) | $2.69M | - |
| EPS - Basic | ($0.14) | - | ($0.15) | ($0.20) | ($0.02) | - | $0.08 | ($0.47) | $0.08 | - |
| EPS - Diluted | ($0.14) | - | ($0.15) | ($0.20) | ($0.02) | - | $0.08 | ($0.47) | $0.08 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $105.58M | $108.74M | $99.13M | $81.19M | $80.70M | $81.63M | $64.02M | $69.60M | $5.24M | $17.09M |
| Accounts Receivable | $176.64M | $167.51M | $180.21M | $201.69M | $219.79M | $223.24M | $244.99M | $242.33M | $357.46M | $372.35M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | $2.04M | - | - | - | $5.74M | - | - | - | $3.04M |
| Current Assets | $298.30M | $293.59M | $295.11M | $309.06M | $325.20M | $335.00M | $336.59M | $337.76M | $387.32M | $415.15M |
| Total Assets | $451.07M | $448.95M | $538.23M | $553.82M | $576.24M | $589.25M | $597.42M | $602.88M | $648.44M | $679.32M |
| Current Liabilities | $90.57M | $77.76M | $85.54M | $96.17M | $109.05M | $120.40M | $120.68M | $110.11M | $128.44M | $148.59M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $138.27M | $126.13M | $130.09M | $141.58M | $158.03M | $170.29M | $172.73M | $163.82M | $180.25M | $205.92M |
| Stockholders' Equity | $312.81M | $322.82M | $408.14M | $412.24M | $418.21M | $418.96M | $424.69M | $439.06M | $468.19M | $473.39M |
| Retained Earnings | $118.94M | $123.21M | $206.14M | $210.91M | $217.57M | $218.06M | $221.81M | $225.00M | $241.05M | $238.36M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.77M | - | - | - | $5.68M | - | - | - | $6.01M | - |
| Investing Cash Flow | ($1.46M) | - | - | - | ($1.89M) | - | - | - | ($2.21M) | - |
| Financing Cash Flow | ($6.46M) | - | - | - | ($4.72M) | - | - | - | ($15.65M) | - |
| CapEx | $1.46M | - | - | - | $1.89M | - | - | - | $2.21M | - |
| Free Cash Flow | $3.31M | - | - | - | $3.79M | - | - | - | $3.80M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1.7% | - | -2.4% | -2.1% | -0.3% | - | 0.9% | -5.7% | 0.8% | - |
| EBITDA margin | -0.2% | - | -0.8% | -0.6% | 1.3% | - | 2.3% | -4.3% | 2.0% | - |
| Net margin | -1.8% | - | -1.9% | -2.4% | -0.2% | - | 0.8% | -4.7% | 0.7% | - |
| Free cash flow margin | 1.4% | - | - | - | 1.3% | - | - | - | 1.0% | - |
| FCF / Net income | -0.78 | - | - | - | -7.74 | - | - | - | 1.41 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 19.0% | - | 18.8% | 18.3% | 17.9% | - | 17.2% | 17.7% | 16.7% | - |
| Effective tax rate | - | - | - | - | - | - | 24.6% | - | 27.0% | - |
| Return on assets | -0.9% | - | -0.9% | -1.2% | -0.1% | - | 0.4% | -2.7% | 0.4% | - |
| Return on equity | -1.4% | - | -1.2% | -1.6% | -0.1% | - | 0.6% | -3.7% | 0.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.29 | 3.78 | 3.45 | 3.21 | 2.98 | 2.78 | 2.79 | 3.07 | 3.02 | 2.79 |
| Quick ratio | 3.29 | 3.78 | 3.45 | 3.21 | 2.98 | 2.78 | 2.79 | 3.07 | 3.02 | 2.79 |
| Cash ratio | 1.17 | 1.40 | 1.16 | 0.84 | 0.74 | 0.68 | 0.53 | 0.63 | 0.04 | 0.12 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -7.3x | - | -10.7x | -10.7x | -2.1x | - | 5.2x | -33.8x | 6.3x | - |
| Equity multiplier | 1.44 | 1.39 | 1.32 | 1.34 | 1.38 | 1.41 | 1.41 | 1.37 | 1.38 | 1.43 |
| Liabilities / Assets | 0.31 | 0.28 | 0.24 | 0.26 | 0.27 | 0.29 | 0.29 | 0.27 | 0.28 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | 0.53 | - | 0.46 | 0.49 | 0.51 | - | 0.53 | 0.56 | 0.58 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 267d | - | 263d | 269d | 273d | - | 284d | 260d | 344d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | 168.0x | - | 234.0x | - |
| P / B | 0.9x | - | 1.1x | 1.0x | 1.1x | - | 1.0x | 1.1x | 1.4x | - |
| P / S | 1.2x | - | 1.8x | 1.5x | 1.6x | - | 1.4x | 1.4x | 1.7x | - |
| EV / EBITDA | - | - | - | - | 105.4x | - | 51.7x | - | 84.9x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -17.8% | - | -20.6% | -19.3% | -22.6% | - | -28.8% | -37.2% | -39.1% | - |
| Revenue CAGR (3y) | -27.1% | - | -26.7% | -28.6% | -28.1% | - | -5.6% | 0.8% | 4.8% | - |
| Revenue CAGR (5y) | -6.0% | - | 5.2% | 4.8% | 6.9% | - | 8.5% | 10.9% | 14.2% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -325.3% | - | - | 69.5% | - | - | -85.9% | - | -93.3% | - |
| Net income growth (YoY) | -770.6% | - | - | 58.5% | - | - | -80.1% | - | -90.9% | - |
| EPS growth (YoY) | -600.0% | - | - | 57.4% | - | - | -77.8% | - | -90.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -12.8% | - | - | - | -0.2% | - | - | - | -91.2% | - |
| FCF CAGR (5y) | - | - | - | - | -25.2% | - | - | - | -20.1% | - |
| Book value growth (YoY) | -25.2% | -22.9% | -3.9% | -6.1% | -10.7% | -11.5% | -9.6% | -6.7% | 3.6% | 3.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.05B totalNurse And Allied Staffing$862.78M · 81.8%
Physician Staffing$191.51M · 18.2%
Product / service
$862.78M totalTemporary Staffing Services$841.78M · 97.6%
Other Services$21.00M · 2.4%
Peer comparison
Same SIC group: Services-Help Supply Services
Comparing CROSS COUNTRY HEALTHCARE INC against the 5 most active filers in the same SIC group.